Latest Neostem (NBS) Headlines NeoStem Announce
Post# of 24
Posted On: 03/14/2014 6:11:44 AM
Latest Neostem (NBS) Headlines
NeoStem Announces 2013 Year End Financial Results and Provides Corporate Update
GlobeNewswire - Thu Mar 13, 3:30PM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company") today announced 2013 year end results and provided an update on its business.
Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016
M2 - Wed Mar 12, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq46f/regenerative) has announced the addition of the "Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016" report to their offering. There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market. According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Vendor Landscape 8. Buying Criteria 9. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis 15. Other Reports in this Series Companies Mentioned: - Advanced Cell Technology Inc. - Arteriocyte Inc. - Athersys Inc. - Baxter International Inc. - CryoLife - Cytori Therapeutics Inc. - Genzyme Corp. - Geron Corp. - InVivo Therapeutics - Inc. - Integra Life Sciences Holdings Corp. - Kensey Nash Corp. - Kinetic Concepts Inc. - Medtronic Inc. - NeoStem Inc. - Osiris Therapeutics Inc. - Osteotech Inc. - RTI Biologics Inc. - Stryker Corp. - Zimmer Holdings Inc. For more information visit http://www.researchandmarkets.com/research/4l...generative
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
NeoStem's Subsidiary, Progenitor Cell Therapy (PCT), Announces Bi-Coastal Facility Expansions
GlobeNewswire - Mon Mar 10, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized contract development and manufacturing organization, announced today that PCT has expanded both its Allendale, NJ and Mountain View, CA current Good Manufacturing Practice ("cGMP") facilities to significantly increase its engineering and process development laboratories, and controlled environment ("clean room") space available for client needs. Furthermore, the expansion in the Allendale, NJ facility features an ISO Class 6/1,000 clean room, enabling PCT to manufacture products intended for European distribution.
NeoStem and Mass. Eye and Ear/Schepens Eye Research Institute Announce Second Research Collaboration Exploring NeoStem's VSEL(TM) Technology for Retinal Repair
GlobeNewswire - Thu Mar 06, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that it has entered into a sponsored research collaboration with Massachusetts Eye and Ear/Schepens Eye Research Institute, an affiliate of Harvard Medical School.
NeoStem to Present at Multiple March Conferences
GlobeNewswire - Thu Feb 27, 6:44AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company will present at multiple conferences in March.
3 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Wed Feb 26, 5:00AM CST
These under-$10 biotech stocks are within range of triggering breakout trades.
Periodontitis - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 21, 2:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/h4fxc9/periodontitis) has announced the addition of the "Periodontitis - Pipeline Review, H2 2013" report to their offering. 'Periodontitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Periodontitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Periodontitis. Scope - A snapshot of the global therapeutic scenario for Periodontitis. - A review of the Periodontitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Periodontitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Periodontitis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Periodontitis - Therapeutics Assessment Drug Profiles trafermin - Drug Profile simvastatin - Drug Profile Asterias - Drug Profile Stem Cell Therapy For Osteoporosis And Bone Regeneration - Drug Profile C5a Receptor Antagonist - Drug Profile OPM-3023 - Drug Profile Drug For Biofilms - Drug Profile ANR Program for Periodontitis - Drug Profile POD CRC-OHS - Drug Profile Antibacterial Agent - Drug Profile Sharon-3000 - Drug Profile Drug For Periodontal Disease - Drug Profile Product Description Mechanism of Action R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Aphios Corporation Kaken Pharmaceutical Co., Ltd. CSL Limited NeoStem, Inc. Onepharm Research and Development GmbH Canopus BioPharma Incorporated Ensoltek Co., Ltd. OTR3 For more information visit http://www.researchandmarkets.com/research/h4...iodontitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
NeoStem CEO Dr. Robin Smith Interviewed on Clear Channel's "The Traders Network" Business Talk Radio
Marketwire - Wed Feb 19, 7:32AM CST
NeoStem, Inc. (NASDAQ: NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that Dr. Robin L. Smith, Chairman and CEO, was interviewed live on Clear Channel's "The Traders Network" hosted by Michael Yorba. This was Dr. Smith's second appearance on The Traders Network. In a two-part interview, Dr. Smith explained the Company's 2014 goals, 2013 achievements, and the increased visibility the Company is achieving in the cell therapy industry.
CEO Dr. Robin Smith of NeoStem to Be Interviewed Live Today on Clear Channel Business Talk Radio DFW 1190AM
Marketwire - Wed Feb 12, 8:45AM CST
NeoStem, Inc. (NASDAQ: NBS) ("NeoStem"), a leader in the emerging cellular therapy industry, today announced that Chairman and CEO Dr. Robin L. Smith will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network. All investors, analysts, industry professionals and prospective customers that are interested to learn more about NeoStem, its goals and recent developments are invited to tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.
NeoStem Expands Treg International Patent Portfolio With Granting of Patent in Japan
GlobeNewswire - Tue Feb 04, 9:48PM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, today announced the expansion of intellectual property protection surrounding the Company's T-regulatory cell ("Treg") program with the grant of Japanese Patent Number 5409827 titled "Methods for the Isolation and Expansion of Cord Blood Derived T Regulatory Cells." This grant further expands the scope and reach of NeoStem's Treg patent estate internationally.
NeoStem to Present at Multiple February Conferences
GlobeNewswire - Mon Feb 03, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), will present at multiple conferences in February.
NeoStem Inc names Dr David Altarac as VP of Regulatory Affairs
M2 - Wed Jan 29, 3:58AM CST
Cellular therapy company NeoStem Inc (NasdaqCM:NBS) revealed on Tuesday the election of appointment of Dr David Altarac as vice president of its Regulatory Affairs.
NeoStem Welcomes David Altarac, M.D., as Vice President, Regulatory Affairs
GlobeNewswire - Tue Jan 28, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today the appointment of Dr. David Altarac as Vice President, Regulatory Affairs. In this position, Dr. Altarac will lead NeoStem's regulatory affairs operations as it grows in connection with the Company's therapeutic pipeline expansion in 2014 and beyond.
ZTE offers industry-first solution for seamless upgrade from PTN to POTN
M2 - Wed Jan 15, 8:31AM CST
ZTE Corporation ("ZTE") (H share stock code: 0763.HK / A share stock code: 000063.SZ), a publicly-listed global provider of telecommunications equipment, network solutions and mobile devices has released the ZXCTN 6500 300mm T-class large capacity POTN product. This product is the first solution for the unified evolution from packet transport network (PTN) to packet optical transport network (POTN) in the industry.
NeoStem and its Subsidiary, Progenitor Cell Therapy (PCT), to Present at Five Sessions at the 2014 Phacilitate Cell & Gene Therapy Forum
GlobeNewswire - Mon Jan 13, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized contract development and manufacturing organization, announced today that NeoStem and PCT will present at five sessions at the Phacilitate Cell & Gene Therapy Forum 2014 in Washington DC.
Nasdaq stocks posting largest percentage decreases
AP - Fri Jan 10, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Biotech Stock Mailbag: NeoStem, MannKind, Inovio
at The Street - Fri Jan 10, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
FIFTH & PACIFIC COMPANIES, INC. ANNOUNCES Q4 2013 DIRECT-TO-CONSUMER COMPARABLE SALES AND PRELIMINARY FULL YEAR 2013 RESULTS
Thomson Reuters ONE - Thu Jan 09, 3:04PM CST
- Expects full year 2013 adjusted EBITDA in the range of $125 to $130 million, inclusive of Lucky Brand results and excluding Juicy Couture results
NeoStem Announces 2013 Year End Financial Results and Provides Corporate Update
GlobeNewswire - Thu Mar 13, 3:30PM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company") today announced 2013 year end results and provided an update on its business.
Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016
M2 - Wed Mar 12, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq46f/regenerative) has announced the addition of the "Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016" report to their offering. There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market. According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Vendor Landscape 8. Buying Criteria 9. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis 15. Other Reports in this Series Companies Mentioned: - Advanced Cell Technology Inc. - Arteriocyte Inc. - Athersys Inc. - Baxter International Inc. - CryoLife - Cytori Therapeutics Inc. - Genzyme Corp. - Geron Corp. - InVivo Therapeutics - Inc. - Integra Life Sciences Holdings Corp. - Kensey Nash Corp. - Kinetic Concepts Inc. - Medtronic Inc. - NeoStem Inc. - Osiris Therapeutics Inc. - Osteotech Inc. - RTI Biologics Inc. - Stryker Corp. - Zimmer Holdings Inc. For more information visit http://www.researchandmarkets.com/research/4l...generative
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
NeoStem's Subsidiary, Progenitor Cell Therapy (PCT), Announces Bi-Coastal Facility Expansions
GlobeNewswire - Mon Mar 10, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized contract development and manufacturing organization, announced today that PCT has expanded both its Allendale, NJ and Mountain View, CA current Good Manufacturing Practice ("cGMP") facilities to significantly increase its engineering and process development laboratories, and controlled environment ("clean room") space available for client needs. Furthermore, the expansion in the Allendale, NJ facility features an ISO Class 6/1,000 clean room, enabling PCT to manufacture products intended for European distribution.
NeoStem and Mass. Eye and Ear/Schepens Eye Research Institute Announce Second Research Collaboration Exploring NeoStem's VSEL(TM) Technology for Retinal Repair
GlobeNewswire - Thu Mar 06, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that it has entered into a sponsored research collaboration with Massachusetts Eye and Ear/Schepens Eye Research Institute, an affiliate of Harvard Medical School.
NeoStem to Present at Multiple March Conferences
GlobeNewswire - Thu Feb 27, 6:44AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company will present at multiple conferences in March.
3 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Wed Feb 26, 5:00AM CST
These under-$10 biotech stocks are within range of triggering breakout trades.
Periodontitis - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 21, 2:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/h4fxc9/periodontitis) has announced the addition of the "Periodontitis - Pipeline Review, H2 2013" report to their offering. 'Periodontitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Periodontitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Periodontitis. Scope - A snapshot of the global therapeutic scenario for Periodontitis. - A review of the Periodontitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Periodontitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Periodontitis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Periodontitis - Therapeutics Assessment Drug Profiles trafermin - Drug Profile simvastatin - Drug Profile Asterias - Drug Profile Stem Cell Therapy For Osteoporosis And Bone Regeneration - Drug Profile C5a Receptor Antagonist - Drug Profile OPM-3023 - Drug Profile Drug For Biofilms - Drug Profile ANR Program for Periodontitis - Drug Profile POD CRC-OHS - Drug Profile Antibacterial Agent - Drug Profile Sharon-3000 - Drug Profile Drug For Periodontal Disease - Drug Profile Product Description Mechanism of Action R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Aphios Corporation Kaken Pharmaceutical Co., Ltd. CSL Limited NeoStem, Inc. Onepharm Research and Development GmbH Canopus BioPharma Incorporated Ensoltek Co., Ltd. OTR3 For more information visit http://www.researchandmarkets.com/research/h4...iodontitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
NeoStem CEO Dr. Robin Smith Interviewed on Clear Channel's "The Traders Network" Business Talk Radio
Marketwire - Wed Feb 19, 7:32AM CST
NeoStem, Inc. (NASDAQ: NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that Dr. Robin L. Smith, Chairman and CEO, was interviewed live on Clear Channel's "The Traders Network" hosted by Michael Yorba. This was Dr. Smith's second appearance on The Traders Network. In a two-part interview, Dr. Smith explained the Company's 2014 goals, 2013 achievements, and the increased visibility the Company is achieving in the cell therapy industry.
CEO Dr. Robin Smith of NeoStem to Be Interviewed Live Today on Clear Channel Business Talk Radio DFW 1190AM
Marketwire - Wed Feb 12, 8:45AM CST
NeoStem, Inc. (NASDAQ: NBS) ("NeoStem"), a leader in the emerging cellular therapy industry, today announced that Chairman and CEO Dr. Robin L. Smith will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network. All investors, analysts, industry professionals and prospective customers that are interested to learn more about NeoStem, its goals and recent developments are invited to tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.
NeoStem Expands Treg International Patent Portfolio With Granting of Patent in Japan
GlobeNewswire - Tue Feb 04, 9:48PM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, today announced the expansion of intellectual property protection surrounding the Company's T-regulatory cell ("Treg") program with the grant of Japanese Patent Number 5409827 titled "Methods for the Isolation and Expansion of Cord Blood Derived T Regulatory Cells." This grant further expands the scope and reach of NeoStem's Treg patent estate internationally.
NeoStem to Present at Multiple February Conferences
GlobeNewswire - Mon Feb 03, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), will present at multiple conferences in February.
NeoStem Inc names Dr David Altarac as VP of Regulatory Affairs
M2 - Wed Jan 29, 3:58AM CST
Cellular therapy company NeoStem Inc (NasdaqCM:NBS) revealed on Tuesday the election of appointment of Dr David Altarac as vice president of its Regulatory Affairs.
NeoStem Welcomes David Altarac, M.D., as Vice President, Regulatory Affairs
GlobeNewswire - Tue Jan 28, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today the appointment of Dr. David Altarac as Vice President, Regulatory Affairs. In this position, Dr. Altarac will lead NeoStem's regulatory affairs operations as it grows in connection with the Company's therapeutic pipeline expansion in 2014 and beyond.
ZTE offers industry-first solution for seamless upgrade from PTN to POTN
M2 - Wed Jan 15, 8:31AM CST
ZTE Corporation ("ZTE") (H share stock code: 0763.HK / A share stock code: 000063.SZ), a publicly-listed global provider of telecommunications equipment, network solutions and mobile devices has released the ZXCTN 6500 300mm T-class large capacity POTN product. This product is the first solution for the unified evolution from packet transport network (PTN) to packet optical transport network (POTN) in the industry.
NeoStem and its Subsidiary, Progenitor Cell Therapy (PCT), to Present at Five Sessions at the 2014 Phacilitate Cell & Gene Therapy Forum
GlobeNewswire - Mon Jan 13, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized contract development and manufacturing organization, announced today that NeoStem and PCT will present at five sessions at the Phacilitate Cell & Gene Therapy Forum 2014 in Washington DC.
Nasdaq stocks posting largest percentage decreases
AP - Fri Jan 10, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Biotech Stock Mailbag: NeoStem, MannKind, Inovio
at The Street - Fri Jan 10, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
FIFTH & PACIFIC COMPANIES, INC. ANNOUNCES Q4 2013 DIRECT-TO-CONSUMER COMPARABLE SALES AND PRELIMINARY FULL YEAR 2013 RESULTS
Thomson Reuters ONE - Thu Jan 09, 3:04PM CST
- Expects full year 2013 adjusted EBITDA in the range of $125 to $130 million, inclusive of Lucky Brand results and excluding Juicy Couture results
(0)
(0)Lisata Therapeutics Inc. (LSTA) Stock Research Links
Scroll down for more posts ▼